Lipoprotein(a) and the cardiovascular drug frontier — the emerging recognition of elevated Lp(a) as a genetically determined independent cardiovascular risk factor affecting approximately twenty percent of the global population — combined with the clinical development of multiple agents specifically targeting Lp(a) reduction — creating what may become the next major...

By mid-2026, the industry has officially entered the era of "Alternative Metabolic Pathways." This year, the focus is on the record-breaking success of Bempedoic Acid and ANGPTL3 Inhibitors. This innovation is a primary driver for the market, as the Hyperlipidemia Drug Market has successfully addressed the "Statin Gap"—the roughly 10-15% of patients who suffer from debilitating muscle...